Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Yongwei Su, Xinyu Li, Holly Edwards, BS, Lisa Polin, PhD, Juiwanna Kushner, Sijana H Dzinic, PhD, Katie Hege, Yu Fukuda, John D. Schuetz, PhD, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, MD, Yubin Ge, PhD

Blood (2018) 132 (Supplement 1): 3936.

https://doi.org/10.1182/blood-2018-99-116997

Published: 2018

Journal Articles

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

Varun Vijay Prabhu, BPharm, MS, PhD, Mala Kiran Talekar, MD, Amriti R Lulla, MS, C. Leah B Kline, Lanlan Zhou, Junior Hall, A. Pieter J Van den Heuvel, David T Dicker, Stephan A Grupp, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Jeffrey J Pu, David F Claxton, MD, Wolfgang Oster, MD, Joshua E. Allen, PhD, Wafik S. El-Deiry

Blood (2017) 130 (Supplement 1): 3842.

https://doi.org/10.1182/blood.V130.Suppl_1.3842.3842

Published: 2017

Journal Articles

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

Yongwei Su, Xinyu Li, Holly Edwards, Joshua E. Allen, PhD, Martin Stogniew, Varun Vijay Prabhu, BPharm, MS, PhD, Jeffrey W. Taub, MD, Hai Lin, Yubin Ge, PhD

Blood (2017) 130 (Supplement 1): 3822.

https://doi.org/10.1182/blood.V130.Suppl_1.3822.3822

Published: 2017

Journal Articles

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Vivian Ruvolo, PhD, Neel Madhukar, Ran Zhao, Hong Mu, MD PhD, Lauren Heese, Kensuke Kojima, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Neil Charter, Sean Deacon, Olivier Elemento, PhD, Joshua E. Allen, PhD, Wolfgang Oster, MD, Martin Stogniew, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2616.

https://doi.org/10.1182/blood.V130.Suppl_1.2616.2616

Published: 2017

Journal Articles

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Jorge Enrique Romaguera, Hun Ju Lee, MD, Rohinton Tarapore, PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Joshua E. Allen, PhD, Lee Schalop, MD, Andrew Zloza, MD, Chi Young Ok, MD, Maria Badillo, Michael Wang, BS

Blood (2017) 130 (Supplement 1): 5163.

https://doi.org/10.1182/blood.V130.Suppl_1.5163.5163

Published: 2017

Journal Articles

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Varun V Prabhu, PhD, Amriti Lulla, Christina L Kline, PhD, Peter J Van den Heuvel, PhD, Mala K. Talekar, MD, Jessica M Wagner, Rohinton S Tarapore, PhD, David T Dicker, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jeffrey J. Pu, MD PhD, David F. Claxton, MD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD, Wafik S. El-Deiry, MD PhD

Blood (2016) 128 (22): 2759.

https://doi.org/10.1182/blood.V128.22.2759.2759

Published: 2016

Journal Articles

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Gautam Borthakur, MD, Jo Ishizawa, MD PhD, Courtney D DiNardo, MD, Tapan M. Kadia, MD, Katherine Weise, Joshua E Allen, PhD, Wolfgang Oster, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 3997.

https://doi.org/10.1182/blood.V128.22.3997.3997

Published: 2016

Journal Articles

ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma

Yong-sheng Tu, PhD, Jin He, M.S., Huan Liu, PhD, Richard Eric Davis, MD, Robert Z. Orlowski, MD, PhD, Joshua E Allen, PhD, Jing Yang, PhD

Blood (2016) 128 (22): 4476.

https://doi.org/10.1182/blood.V128.22.4476.4476

Published: 2016

Journal Articles

ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Ran Zhao, Jianfang Zeng, MD PhD, Dhruv Chachad, Kensuke Kojima, MD PhD, Marina Konopleva, MD PhD, Richard Eric Davis, MD, Joshua E Allen, PhD, Martin Stogniew, PhD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 4059.

https://doi.org/10.1182/blood.V128.22.4059.4059

Published: 2016

Journal Articles

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Varun V Prabhu, PhD, Rohinton S Tarapore, PhD, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jessica M Wagner, Wafik S. El-Deiry, MD PhD, Martin Stogniew, PhD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD

Blood (2016) 128 (22): 5133.

https://doi.org/10.1182/blood.V128.22.5133.5133

Published: 2016

Journal Articles

ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies

Joshua E. Allen, PhD, Jo Ishizawa, MD PhD, Wafik S. El-Deiry, MD PhD F.A.C.P, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 4812.

https://doi.org/10.1182/blood.V124.21.4812.4812

Published: 2014

Journal Articles

ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition

Jo Ishizawa, MD PhD, Kensuke Kojima, MD PhD, Dhruv Chachad, MS, Peter P. Ruvolo, PhD, Vivian R Ruvolo, MA, Rodrigo Jacamo, PhD, Archana Dilip, MS, Hong Mu, MD PhD, Zhihong Zeng, MD, Polina Matre, PhD, Joshua E. Allen, PhD, Sattva S Neelapu, MD, Timothy J. McDonnell, MD PhD, Roberto N. Miranda, MD, Larry W. Kwak, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, R Eric Davis, MD, Michael Andreeff, MD PhD

Blood (2014) 124 (21): 3122.

https://doi.org/10.1182/blood.V124.21.3122.3122

Published: 2014

Journal Articles

ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples

Varun Vijay Prabhu, Jo Ishizawa, MD PhD, Dan Zhao, MD PhD, Joshua E. Allen, PhD, Tracy T. Batchelor, MD, Andrew S. Chi, MD PhD, Michael Andreeff, MD PhD, Wafik S. El-Deiry, MD PhD F.A.C.P

Blood (2014) 124 (21): 5219.

https://doi.org/10.1182/blood.V124.21.5219.5219

Published: 2014

Journal Articles

Caspase-Dependent Anti-Tumor Effects of ONC201/TIC10 on Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Amriti R. Lulla, Christina Leah B Kline, PhD, Liz J. Hernandez-Borrero, Varun Vijay Prabhu, Jessica M Wagner, David T. Dicker, Nathan G. Dolloff, PhD, Brian M Barth, PhD, Jeffrey J Pu, MD PhD, David F. Claxton, MD, Joshua E. Allen, PhD, Wafik S. El-Deiry, MD PhD FACP

Blood (2014) 124 (21): 5224.

https://doi.org/10.1182/blood.V124.21.5224.5224

Published: 2014

Journal Articles

Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells

Jessica M Wagner, Varun Vijay Prabhu, Leah L. Kline, PhD, Amriti R. Lulla, Liz J. Hernandez-Borrero, Jeffrey J. Pu, MD PhD, David T. Dicker, Brian M Barth, PhD, David F. Claxton, MD, Joshua E. Allen, PhD, Wafik S. El-Deiry, MD PhD FACP

Blood (2014) 124 (21): 5233.

https://doi.org/10.1182/blood.V124.21.5233.5233

Published: 2014

Journal Articles

Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins

Varun Vijay Prabhu, Amriti R. Lulla, Jessica M Wagner, Liz J. Hernandez-Borrero, Mala K. Talekar, MD, Christina L. Kline, PhD, David T. Dicker, Brian M Barth, PhD, Jeffrey J. Pu, MD PhD, David F. Claxton, MD, Joshua E. Allen, PhD, Wafik S. El-Deiry, MD PhD FACP

Blood (2014) 124 (21): 5237.

https://doi.org/10.1182/blood.V124.21.5237.5237

Published: 2014

Journal Articles

ONC201(TIC10) Induces TRAIL and Cell Death In Preclinical Models Of Pediatric Lymphoma

Mala Kiran Talekar, MD, Joshua E Allen, PhD, Wafik S. El-Deiry, M.D, Ph.D, F.A.C.P

Blood (2013) 122 (21): 1671.

https://doi.org/10.1182/blood.V122.21.1671.1671

Published: 2013

Journal Articles

ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas

Jo Ishizawa, MD, PhD, Kensuke Kojima, MD, PhD, Archana Dilip, MS, Vivian R Ruvolo, MA, Bing Z Carter, PhD, Joshua E Allen, PhD, Sattva S. Neelapu, MD, Timothy J. McDonnell, MD, PhD, Mala Kiran Talekar, MD, Wafik S. El-Deiry, MD, Larry W. Kwak, MD, PhD, Michael Andreeff, MD, PhD

Blood (2013) 122 (21): 3822.

https://doi.org/10.1182/blood.V122.21.3822.3822

Published: 2013

NARROW

Venetoclax Synergistically Enhances the Antileukemic Activity of Imipridone ONC213, a Novel Imipridone ONC201 Analog, in Acute Myeloid Leukemia

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

ONC213, a Novel Second Generation Analog of ONC201, Shows Promising Anti-Leukemic Activity Against AML Cells In Vitro and In Vivo

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

ONC201 Overcomes Chemotherapy Resistance By Upregulation of Bim in Multiple Myeloma

ONC212 Is a Potent Member of the Imipridone Class of Anti-Cancer Compounds That Induces p53-Independent Apoptosis in Hematological Malignancies

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

ONC201 Possesses a Benign Safety Profile at Highly Efficacious Doses in Normal Human Cells and Animal Toxicology Studies

ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition

ONC201 Depletes Cancer Stem Cells in Refractory Cancer Patient Samples

Caspase-Dependent Anti-Tumor Effects of ONC201/TIC10 on Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Screen of Small Molecule ONC201/TIC10 Identifies Single Agent Activity and Combinatorial Efficacy with Bortezomib, Rituximab or Dexamethasone in Killing of Acute Lymphoblastic Leukemia Cells

Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins

ONC201(TIC10) Induces TRAIL and Cell Death In Preclinical Models Of Pediatric Lymphoma

ONC201 Exerts p53-Independent Cytotoxicity Through TRAIL and DR5 Induction In Mantle Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only